3 Drugs Stocks Driving The Industry Higher
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
All three major indices are trading down today with the
Dow Jones Industrial Average
(
^DJI
) trading down 199 points (-1.1%) at 17,696 as of Friday, March 13, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 614 issues advancing vs. 2,348 declining with 137 unchanged.
The Drugs industry currently sits down 0.4% versus the S&P 500, which is down 0.8%. Top gainers within the industry include
(
), up 13.7%, and
(
), up 2.1%. On the negative front, top decliners within the industry include
(
), down 3.4%,
(
), down 3.5%,
(
), down 3.5%,
(
), down 1.7% and
(
), down 1.4%.
TheStreet would like to highlight 3 stocks pushing the industry higher today:
3.
(
) is one of the companies pushing the Drugs industry higher today. As of noon trading, Regeneron Pharmaceuticals is up $5.66 (1.3%) to $430.82 on average volume. Thus far, 497,022 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 853,100 shares. The stock has ranged in price between $424.50-$435.00 after having opened the day at $425.00 as compared to the previous trading day's close of $425.16.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals has a market cap of $42.7 billion and is part of the health care sector. Shares are up 3.6% year-to-date as of the close of trading on Thursday. Currently there are 10 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 9 rate it a hold.
TheStreet Ratings rates
Regeneron Pharmaceuticals
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full
Regeneron Pharmaceuticals Ratings Report
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
2. As of noon trading,
Valeant Pharmaceuticals International
(
) is up $1.30 (0.7%) to $193.92 on average volume. Thus far, 1.8 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $192.68-$194.96 after having opened the day at $194.50 as compared to the previous trading day's close of $192.62.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. Valeant Pharmaceuticals International has a market cap of $65.1 billion and is part of the health care sector. Shares are up 34.6% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold.
TheStreet Ratings rates
Valeant Pharmaceuticals International
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full
Valeant Pharmaceuticals International Ratings Report
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
1. As of noon trading,
(
) is up $5.32 (1.3%) to $412.96 on average volume. Thus far, 881,708 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $407.09-$416.70 after having opened the day at $407.09 as compared to the previous trading day's close of $407.64.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen Idec has a market cap of $95.7 billion and is part of the health care sector. Shares are up 20.1% year-to-date as of the close of trading on Thursday. Currently there are 12 analysts who rate Biogen Idec a buy, no analysts rate it a sell, and 4 rate it a hold.
TheStreet Ratings rates
Biogen Idec
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
null